Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

Novo Nordisk Receives Complete Response Letter for Once-Weekly Insulin Icodec in US

Jul 10, 2024

On 10 July 2024, Novo Nordisk announced that the FDA has issued a Complete Response Letter (CRL) regarding its BLA for once-weekly week insulin icodec for diabetes mellitus.  The CRL is said to include “requests related to the manufacturing process and the type 1 diabetes indication”.

Insulin icodec, under the brand name Awiqli®, was recommended for EU approval on 22 March 2024 and subsequently received EU marketing authorisation for treating diabetes in May 2024.  Awiqli® has been approved in Switzerland and Canada (March 2024) and Japan and Australia (June 2024) and was endorsed in China in June 2024 for Type 2 diabetes.  Novo Nordisk’s weekly insulin icodec injection is close to approval in India.